---
title: "12 Health Care Stocks Moving In Tuesday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296256261.md"
description: "During Tuesday's intraday session, several healthcare stocks experienced significant volatility. Gainers included AIxCrypto Hldgs (AIXC) up 132%, Amylyx Pharmaceuticals (AMLX) up 54.45%, and China SXT Pharmaceuticals (SXTC) up 30.13%. Conversely, losers saw DocGo (DCGO) drop 26.7%, ALPS Group (ALPS) fall 16.93%, and BioVie (BIVI) decline 16.24%. Many movements coincided with recent earnings reports."
datetime: "2026-08-18T17:05:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296256261.md)
  - [en](https://longbridge.com/en/news/296256261.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296256261.md)
---

# 12 Health Care Stocks Moving In Tuesday's Intraday Session

### Gainers

-   **AIxCrypto Hldgs** (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million.
-   **Amylyx Pharmaceuticals** (NASDAQ:AMLX) stock increased by 54.45% to $33.1. The company's market cap stands at $2.3 billion.
-   **China SXT Pharmaceuticals** (NASDAQ:SXTC) stock moved upwards by 30.13% to $4.88. The company's market cap stands at $2.0 million.
-   **OSR Health** (NASDAQ:OSRH) shares rose 25.52% to $0.74. The market value of their outstanding shares is at $20.7 million. As per the news, the Q2 earnings report came out 2 days ago.
-   **Modular Medical** (NASDAQ:MODD) shares increased by 25.31% to $2.97. The company's market cap stands at $12.8 million. The company's, Q1 earnings came out 2 days ago.
-   **Scribe Therapeutics** (NASDAQ:SCTX) shares moved upwards by 25.15% to $26.52. The company's market cap stands at $342.8 million.

### Losers

-   **DocGo** (NASDAQ:DCGO) stock decreased by 26.7% to $0.52 during Tuesday's regular session. The market value of their outstanding shares is at $70.1 million. As per the press release, Q2 earnings came out yesterday.
-   **ALPS Group** (NASDAQ:ALPS) stock decreased by 16.93% to $0.27. The company's market cap stands at $53.2 million.
-   **BioVie** (NASDAQ:BIVI) shares declined by 16.24% to $0.98. The market value of their outstanding shares is at $8.8 million. As per the news, the Q4 earnings report came out 3 days ago.
-   **Jasper Therapeutics** (NASDAQ:JSPR) stock decreased by 12.61% to $0.74. The market value of their outstanding shares is at $28.0 million. As per the press release, Q2 earnings came out 2 days ago.
-   **NextCure** (NASDAQ:NXTC) stock decreased by 12.52% to $6.75. The company's market cap stands at $35.2 million.
-   **Valion Bio** (NASDAQ:VBIO) shares decreased by 12.11% to $0.16. The company's, Q2 earnings came out 2 days ago. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [ALPS.US](https://longbridge.com/en/quote/ALPS.US.md)
- [AIXC.US](https://longbridge.com/en/quote/AIXC.US.md)
- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)
- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [DCGO.US](https://longbridge.com/en/quote/DCGO.US.md)
- [OSRH.US](https://longbridge.com/en/quote/OSRH.US.md)
- [MODD.US](https://longbridge.com/en/quote/MODD.US.md)
- [SCTX.US](https://longbridge.com/en/quote/SCTX.US.md)
- [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md)
- [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md)
- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)
- [OSRHW.US](https://longbridge.com/en/quote/OSRHW.US.md)
- [ALPWF.US](https://longbridge.com/en/quote/ALPWF.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial](https://longbridge.com/en/news/296265581.md)
- [Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026](https://longbridge.com/en/news/296140552.md)
- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)
- [Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal](https://longbridge.com/en/news/296218787.md)
- [Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level](https://longbridge.com/en/news/296238728.md)